Suspension of ulipristal acetate for uterine fibroids during ongoing EMA’s review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!

OBJECTIVE: EMA decided that with ulipristal acetate (UPA) treatment for uterine fibroids, should be discontinued due to the associated risk of hepatic failure, We analyzed whether the risk of recurrent symptoms due to fibroids may lead to an increased risk of Covid -19 infection and death, that woul...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenberg, Serge, Revercez, Perrine, Fastrez, Maxime, Vandromme, Jean, Bucella, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320679/
https://www.ncbi.nlm.nih.gov/pubmed/32650189
http://dx.doi.org/10.1016/j.ejogrb.2020.06.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320679/
https://www.ncbi.nlm.nih.gov/pubmed/32650189
http://dx.doi.org/10.1016/j.ejogrb.2020.06.064

Ejemplares similares